Loading
BHV-1530 is an experimental antibody-drug conjugate from Biohaven, in phase 1 trials for urothelial cancer and other solid tumours.
BHV-1530 is an antibody-drug conjugate from Biohaven. An antibody-drug conjugate directed at FGFR3. Biohaven's pipeline lists it in phase 1b for urothelial cancer and other tumours; the phase 1 study NCT06874335 tests it alone and with cemiplimab. Whether it works in people has not been established.
An antibody-drug conjugate directed at FGFR3. Connects to FGFR3.
1.BHV-1530's antibody arm binds FGFR3 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"BHV-1530" OR ABSTRACT:"BHV-1530" OR TITLE:"AMB302" OR ABSTRACT:"AMB302") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BHV-1530, not a curated reading list.
Shares Biohaven and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/